Spots Global Cancer Trial Database for A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
Official Title: A Phase 1 Study to Compare Bempegaldesleukin Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (mRCC) (PIVOT IO 011)
Study ID: NCT04540705
Conditions
Study Description
Brief Summary: The purpose of this study is in Part 1, to determine the safety of nivolumab, bempegaldesleukin (BEMPEG: NKTR-214), and Tyrosine Kinase Inhibitor (TKI) combination.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution - 0005, Springdale, Arkansas, United States
Local Institution, Louisville, Kentucky, United States
Local Institution - 0001, Saint Louis, Missouri, United States
Local Institution - 0009, New York, New York, United States
Local Institution, Portland, Oregon, United States
Local Institution, Nashville, Tennessee, United States
Local Institution - 0014, Houston, Texas, United States
Local Institution - 0007, Seattle, Washington, United States
Local Institution - 0025, Mar del Plata, Buenos Aires, Argentina
Local Institution - 0075, Río Cuarto, Córdoba, Argentina
Local Institution - 0026, Buenos Aires, , Argentina
Local Institution - 0024, San Juan, , Argentina
Local Institution - 0030, Belo Horizonte, Minas Gerais, Brazil
Local Institution - 0035, Curitiba, Parana, Brazil
Local Institution - 0028, Porto Alegre, RIO Grande DO SUL, Brazil
Local Institution - 0036, Santa Cruz do Sul, RIO Grande DO SUL, Brazil
Local Institution - 0032, Barretos, SAO Paulo, Brazil
Local Institution - 0029, Sao Jose do Rio Preto, SAO Paulo, Brazil
Local Institution - 0056, Edmonton, Alberta, Canada
Local Institution - 0015, Vancouver, British Columbia, Canada
Local Institution - 0022, St. Johns, Newfoundland and Labrador, Canada
Local Institution - 0008, Toronto, Ontario, Canada
Local Institution - 0079, Marseille, , France
Local Institution - 0042, Essen, , Germany
Local Institution - 0045, Hannover, , Germany
Local Institution - 0040, Jena, , Germany
Local Institution - 0044, Munich, , Germany
Local Institution - 0041, Nürnberg, , Germany
Local Institution - 0046, Würzburg, , Germany
Local Institution - 0048, Mexico City, Distrito Federal, Mexico
Local Institution - 0050, Zapopan, Jalisco, Mexico
Local Institution - 0049, Monterrey, Nuevo LEON, Mexico
Local Institution - 0055, Queretaro, , Mexico
Local Institution - 0059, Moscow, , Russian Federation
Local Institution - 0052, Moscow, , Russian Federation
Local Institution - 0087, Moscow, , Russian Federation
Local Institution - 0051, Novosibirsk, , Russian Federation
Local Institution - 0085, Omsk, , Russian Federation
Local Institution - 0058, Saint Petersburg, , Russian Federation
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
